



## (51) International Patent Classification:

A61K 38/17 (2006.01) A61P 37/06 (2006.01)  
A61K 9/127 (2006.01) C07K 14/775 (2006.01)  
A61P 31/14 (2006.01)

## (21) International Application Number:

PCT/IB2021/000283

## (22) International Filing Date:

15 April 2021 (15.04.2021)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

63/011,055 16 April 2020 (16.04.2020) US  
63/092,070 15 October 2020 (15.10.2020) US  
63/121,640 04 December 2020 (04.12.2020) US

(71) Applicant: **ABIONYX PHARMA SA** [FR/FR]; 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR).

(72) Inventors: **TUPIN, Cyrille**; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR). **PEYROTTE, Constance**; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR). **BARBARAS, Ronald**; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR).

(74) Agent: **HOFFMANN EITLE PATENT- UND RECHTSANWÄLTE PARTMBB, ASSOCIATION NO. 151**; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS FOR TREATING ACUTE CONDITIONS USING LIPID BINDING PROTEIN-BASED COMPLEXES




FIG. 1

(57) Abstract: Methods for treating acute conditions (e.g., acute conditions comprising acute inflammation), such as cytokine release syndrome, sepsis and acute kidney injury using lipid binding protein-based complexes.